Transcranial magnetic stimulation (TMS) is an effective treatment for major depressive disorder (MDD), particularly in individuals resistant to first-line antidepressants.
Introduction
Transcranial magnetic stimulation (TMS) is an effective treatment for major depressive disorder (MDD), particularly in individuals resistant to first-line antidepressants. [1] [2] [3] Effect sizes of TMS from recent meta-analyses range from 0.39 to 0.55. 4, 5 Less is known about the neurobiological mechanisms of antidepressant response to TMS. Emerging evidence suggests that in addition to its effects on the dorsolateral prefrontal cortex (DLPFC), TMS also affects structures to which the DLPFC projects, including the medial prefrontal cortex (MPFC). 6 The MPFC is overactive in individuals with MDD, 7 and functional connectivity between the DLPFC and MPFC predicts response to TMS. [8] [9] [10] Little is known about how connectivity between the DLPFC and MPFC gives rise to the antidepressant effect of TMS.
Other antidepressants appear to act in part by modulating the excitability of cortical circuits. Levels of γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain, which are generally decreased in depressed individuals, 11 have been reported to increase after treatment with selective serotonin reuptake inhibitors (SSRIs) 12 and electroconvulsive therapy (ECT). 13 Although TMS affects the balance of excitation and inhibition in cortical circuits, 14 it is unknown whether changes in excitation-inhibition balance mediate antidepressant response.
In this naturalistic study, we tested whether TMS alters the levels of GABA and those of the combined resonance of glutamate and glutamine (Glx) in patients with MDD. Specifically, the standard J-edited spin echo difference proton magnetic resonance spectroscopy ( 1 H MRS) technique was implemented at 3 T to measure levels of MPFC GABA and
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Glx before and after a 25-day course of 10-Hz TMS treatment over the left DLPFC. Based on the majority of reports in patients with MDD on the neurochemical response to antidepressant therapy, 11, 12, 15 we hypothesized that TMS would selectively increase MPFC GABA levels while minimally affecting those of Glx.
Methods

Participants
Participants in this study were outpatients meeting DSM-IV-TR criteria for a nonpsychotic major depressive episode who provided written informed consent. Patients were referred by the outpatient clinic in the Department of Psychiatry at Weill Cornell Medical College, New York, USA. Also enrolled were self-referred patients who directly contacted our TMS program.
To be eligible, the patients were required to meet criteria for treatment-resistance, defined as a failure to respond to at least 2 previous antidepressant trials at adequate doses for at least 8 weeks during the current episode. Patients were also required to have a minimum score of 18 on the 24-item Hamilton Rating Scale for Depression (HAMD24). Patients were excluded if they were actively suicidal with plan or intent; were pregnant or lactating; had bipolar I disorder or a psychotic disorder; had been in their current episode for longer than 3 years; had a history of clinically significant personality disorder, as established in the diagnostic interview; or had a substance abuse disorder or substance dependence within the past 3 years, metal implants, a history of seizure disorder or other neurologic disorder, or a closed head injury with loss of consciousness.
Participants were allowed to continue prior medications, provided that the doses remained unchanged for 4 weeks before beginning the study and throughout the course of TMS. All aspects of our experimental protocol were approved by the Institutional Review Board of Weill Cornell Medical College and were conducted in accordance with federal and institutional human research guidelines.
Repetitive TMS protocol
All patients completed 25 sessions of rTMS over the left DLPFC over a 5-week period using the NeuroStar TMS Therapy System (Neuronetics, Inc.). We assessed treatment response using the HAMD24 at baseline and 1-3 days after completion of the 5-week course of treatment. Individual sessions consisted of 37.5 min (3000 pulses; 30-s duty cycle, 4 s on, 26 s off) of 10-Hz excitatory TMS daily for 25 days (Monday-Friday for a 5-week period). The standard " Figure  8 " NeuroStar TMS coil was centred over the scalp via the Beam F3 method 16 using surface distances between the nasion, inion, tragus and vertex as landmarks. Resting motor threshold (MT) was defined as the stimulus strength over the thumb area of the motor cortex that produced visually detectable thumb movement on 50% of trials. We measured MT before the first treatment and on every fifth treatment thereafter. We aimed to apply repetitive stimulation at 120% of the resting MT, 1 and applied intensities of 80%-120% (mean 86.4% ± 14.3%) to all participants except for 2, who reported scalp pain above an intensity of 80% of resting MT. Resting MT and stimulation intensity for each participant are described in Appendix 1, Table S2 , available at jpn.ca.
Magnetic resonance neuroimaging procedures
All neuroimaging studies, which included limited structural brain MRI examination and single-voxel 1 H MRS of the MPFC, were conducted on a research-dedicated 3.0 T GE MR system with an 8-channel phased-array head coil at the Citigroup Biomedical Imaging Center of Weill Cornell Medical College. All patients underwent 2 neuroimaging sessions that occurred before (mean 2.5 ± 2.3 d) and shortly after (mean 1.0 ± 1.1 d) completing the 5-week course of TMS.
Structural MRI
A 3-plane, low-resolution, high-speed scout imaging series was obtained, followed by a series of high-resolution scans, consisting of standard axial, coronal and sagittal T 1 -, T 2 -and spin density-weighted scans that were appropriately obliqued for prescribing the 1 H MRS voxel in the MPFC. In addition, we obtained a T 1 -weighted spoiled gradientrecalled echo (SPGR) volumetric scan and an axial Fast FluidAttenuated Inversion Recovery (FLAIR) scan for brain tissue segmentation and detection of exclusionary focal brain lesions, respectively.
H MRS
The GABA-edited 1 H MRS data were acquired using the standard J-edited spin echo difference method 17 and then processed as described recently 16, 18 ( Fig. 1, Appendix 1) . Each spectrum was recorded from a single 2.5 × 2.5 × 3.0 cm voxel prescribed in the MPFC, which includes a rostral component of the anterior cingulate cortex (Fig. 1A and B) .
H MRS data processing and quantitation
Details of the MRS data quality assessment criteria and procedures used in this study to retain or reject spectra for inclusion in group analyses are provided in Appendix 1. For all the cases that fulfilled our quality assessment criteria, spectral peak areas, which are proportional to the concentrations of the associated metabolites, were obtained as illustrated in Fig. 1C (traces [a-f]) . Briefly, the GABA and Glx resonances in the J-edited difference spectra were modelled as a linear combination of pseudo-Voigt lineshape functions and then fitted in the frequency domain using a robust and highly optimized public-domain Levenberg-Marquardt nonlinear least squares minimization routine. 19 For normalization across participants, the GABA and Glx levels were expressed as ratios of peak areas relative to the area of the synchronously acquired and similarly fitted unsuppressed voxel water signal (W). 
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Assessment of voxel tissue heterogeneity
To estimate the proportions of grey matter, white matter and cerebrospinal fluid (CSF) contained in each voxel of interest, we used MEDx software (Medical Numerics) to segment the brain tissue based on the signal-intensity histogram of each participant's volumetric (SPGR) MRI. In-house software developed in MATLAB (MathWorks) was then implemented to generate a segmentation mask for each voxel, from which the proportions of grey matter, white matter and CSF were determined. These were then compared between baseline and post-TMS for the whole group and, in case of significant differences, included in the statistical model as covariates.
Statistical analysis
A TMS responder was defined as having at least a 50% reduction in HAMD24 scores post-TMS compared with baseline. , showing (c) the edited γ-aminobutyric acid (GABA) and combined resonance of glutamate and glutamine (Glx) peaks, with (d) best-fit model spectrum of (c), and (e) the residuals of the difference between the edited (c) and best-fit (d) spectra. The data were acquired in 13 min from a 2.5 × 2.5 × 3.0 cm 3 voxel using an echo time (TE) of 68 ms and a repetition time (TR) of 1500 ms, and 256 interleaved excitations (512 total) with editing pulse on or off. 
Results
Demographics and sample characteristics
In the aggregate, 25 patients with treatment-resistant depression were enrolled in this study, and all completed the 5-week course of TMS. Data for 2 patients were excluded from all the analyses owing to significant differences in head tilt in the magnet between the baseline and post-TMS neuroimaging scans, leaving 23 outpatients for subsequent analyses: 21 with MDD, 2 with bipolar II disorder (mean age 41.7 ± 15.9 yr; 7 [30%] men). The clinical and demographic characteristics of the final sample before and after the 5-week course of TMS are summarized in Table 1 .
The mean lifetime number of major depressive episodes was 4.9 ± 2.4. Two participants had a history of hypomania and thus met a diagnosis of bipolar II disorder. Four patients had psychiatric comorbidities: 1 had attention-deficit/ hyperactivity disorder, 2 had obsessive-compulsive disorder and 1 had generalized anxiety disorder. Of the 23 patients included in the final sample, 19 (83%) were taking antidepressants, and a number were taking mood stabilizers, antipsychotics, or other medications (Appendix 1, Table S1 ).
Effects of TMS treatment on depressive symptoms
On average, patients' depressive symptoms, as assessed using the HAMD24, improved by 9.9 points (from 28.7 to 18.8) from the first to the final TMS treatment sessions (95% confidence interval [CI] -9.0 to -4.3). Depressive symptoms in the 8 responders improved on average by 17.6 points (from 28.1 to 10.5) from the first to the final TMS treatment sessions (95% CI -12.1 to -7.5). In contrast (and by definition), depressive symptoms did not improve in the 15 nonresponders, changing on average by 5.9 points (from 29.1 to 23.2) from the first to the final TMS treatment sessions (95% CI -4.2 to 0.8). Table 2 provides the proportions of grey matter, white matter and CSF in the MPFC voxel for baseline and post-TMS, as determined by tissue segmentation, as well as the mean unsuppressed voxel tissue water signal (W) for baseline and post-TMS. Using paired t tests, we detected no differences in 
H MRS voxel tissue heterogeneity
Primary hypothesis: GABA and Glx levels before and after TMS treatment
In all participants ( Fig. 2A) , mean change in GABA 11.9%, Wilcoxon V = 26, p = 0.06).
If response was defined more liberally as a greater than 30% reduction in HAMD24 scores, 21 there were 12 responders and 11 nonresponders. Among responders, there was a significantly higher mean MPFC GABA level post-TMS than at baseline (3.03 × 10 -3 ± 0.61 × 10 -3 v. 2.63 × 10 -3 ± 0.62 × 10 -3 , mean change in GABA 17.4%, Wilcoxon V = 2, p = 0.001). Among nonresponders, MPFC GABA levels post-TMS were greater than at baseline (2.92 × 10 -3 ± 0.61 × 10 -3 v. 2.70 × 10 -3 ± 0.44 × 10 -3 ); this difference was smaller than in responders and was nonsignificant (mean change in GABA 9.9%, Wilcoxon V = 18, p = 0.21).
The presence of a psychiatric comorbidity influenced the magnitude of change of post-TMS GABA from baseline. One participant in the responder group (defined by 50% reduction in HAMD24 score) had a comorbid disorder (ADHD), and 5 participants in the nonresponder group had comorbidities (2 had bipolar II Disorder, 2 had obsessivecompulsive disorder and 1 had generalized anxiety disorder). The 1 responder with ADHD had a large (55%) increase in post-TMS GABA from baseline, which significantly impacted the average GABA increase in the responder group. Among the 7 responders without comorbidities, there was a significantly higher mean MPFC GABA level post-TMS (mean change in GABA 12.0%, Wilcoxon V = 2, p = 0.047). Among non responders, MPFC GABA levels post-TMS were also larger than at baseline, although this difference did not reach significance (mean change in GABA 10.9%, Wilcoxon V = 11, p = 0.11). 
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In all participants (Fig. 2B) , Wilcoxon V = 75, p = 0.42). Mean MPFC Glx levels remained unchanged when we used the definition of a response of greater than 30% reduction in HAMD24 score and when we removed participants with psychiatric comorbidities from our analyses.
Demographic variables versus GABA and Glx levels before and after TMS
Regression analysis of percent change in GABA with stepwise selection retained age, sex, current SSRI use and daily lorazepam use as predictors, and the model had an adjusted R 2 value of 0.31. Percent GABA change was significantly and positively associated with age (t = 2.15, p = 0.046) and male sex (t = 2.59, p = 0.018) and showed a trend toward significance for a negative association with current use of SSRI (t = -2.09, p = 0.05) and current daily use of lorazepam (t = -1.81, p = 0.09) Percent change in GABA was not associated with baseline HAMD24 score, TMS responder status, TMS intensity, lifetime number of antidepressant trials, or history of antipsychotic or mood stabilizer use.
Exploratory analysis: MPFC GABA versus Glx correlations before and after TMS
Given that metabolic GABA is synthesized from glutamate by the enzyme L-glutamic acid decarboxylase (GAD) and that the GABA shunt converts to glutamate, it is generally of interest to explore associations between the 2 neurotransmitters, especially since they both are postulated to play an important role in many neuropsychiatric disorders, including MDD. 22, 23 Our exploratory investigation of such associations revealed GABA to correlate strongly with Glx in participants with severe depression (i.e., HAMD24 > 27 24 , n = 11) at baseline (r = 0.90, p < 0.001; Fig. 3A) , but not in patients with moderate depression (HDRD24 < = 27, n = 12, r = 0.06, p = 0.86; Fig. 3B ). Post-TMS, GABA and Glx were uncorrelated (r = 0.35, p = 0.29) in the severe depression group (Fig. 3C) , with still no GABA and Glx correlation (r = 0.10, p = 0.77) in the moderate depression group (Fig. 3D ).
Discussion
The novelty of our study is its focus on examining changes in brain GABA and Glx levels in patients with depression before and after a course of therapeutic TMS. We found GABA elevations in the MPFC post-TMS relative to levels at baseline in a cohort of adults with MDD. The GABA elevations were greater in responders than in nonresponders (17.4% v. 11.9%). Differences between responders and nonresponders were more pronounced (17.4% v. 9.9%) if response was defined E43 more liberally as a greater than 30% reduction in HAMD24 scores. In contrast, we found no differences or changes in Glx between baseline and post-TMS.
The main result of the present study, that the antidepressant effect of rTMS was associated with elevation of GABA levels relative to baseline, is consistent with and extends prior observations about GABA in depression and the effects of antidepressant treatments. The observed increase in GABA was also seen in nonresponders, suggesting that GABA increase may contribute to the antidepressant mechanism of TMS, but this association was not causal. Levels of GABA are low in the depressed brain, supported by convergent evidence from CSF samples, 25 GABAergic neuronal density 26 and GAD67 expression 27 in postmortem brains. Prior MRS studies revealed GABA reductions in depressed individuals compared with healthy controls, 11, 28 with more pronounced MPFC reductions in a treatment-refractory subgroup. 15 Further, and also in support of the GABAdeficit hypothesis of depression, a variety of different antidepressants seem to function, in part, by elevating GABA. These include SSRIs, 12 the monoamine-oxidase inhibitor phenelzine, 29 the GABA-reuptake inhibitor tiagabine 30 and ECT. 13 We did not observe changes in Glx levels, either in the whole group or in TMS-responder or nonresponder subgroups. Glx levels have been found to be reduced in the MPFC at baseline in patients with depression, 22 and these levels have normalized in the lateral prefrontal cortex, 31 
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32 and amygdala after ECT; 31 in the DLPFC after TMS for pediatric depression; 33 and in the anterior cingulate cortex in healthy individuals after TMS. 34 The difference between our findings and those previously reported in healthy individuals after TMS may reflect a difference in Glx homeostasis in the MPFC in patients with depression. As already suggested, GABA elevation in the MPFC may contribute to the antidepressant mechanism of TMS. Optogenetic studies in rodents indicate that homeostasis in the ratio of excitation to inhibition in MPFC microcircuits plays a critical role in supporting normal circuit function and PFCdependent behaviours. 35 In patients, GABA deficits may contribute to findings of MPFC hyperactivity and elevated functional connectivity that have been reported in patients with depression, 36 all of which have been shown to normalize after antidepressant treatment with SSRIs, 37 TMS, 9 ECT 38 and deep brain stimulation. 39 The lack of increase of Glx after TMS may highlight a seizure-dependent antidepressant mechanism specific to ECT suggested by postictal elevations in Glutamate after spontaneous seizures. 40 Medial PFC GABA and Glx correlated significantly at baseline but not after TMS owing to elevations in GABA that were unaccompanied by Glx elevations. In keeping with our pre-TMS findings, GABA and Glx in the MPFC have been found to correlate highly in a pooled sample of patients with schizophrenia and healthy controls. 41 Transcranial magnetic stimulation may unlink the GABA and Glx metabolism, change proportions of the pools of protein-bound neurotransmitter, or change compartmental localization.
Elevation of GABA in the MPFC may exert its antidepressant effect in part through its impact on the functional connectivity of resting-state networks. Functional connectivity of the subgenual anterior cingulate decreases during TMS for depression, targeting the left DLPFC 9 and dorsomedial prefrontal cortex 10 while baseline connectivity of the subgenual anterior cingulate predicts response to TMS. 8, 9 The effect of MPFC GABA elevations on functional connectivity of the subgenual anterior cingulate awaits further study.
Limitations
Our study has several limitations. First, it is a naturalistic study, and the lack of a group of healthy controls makes it difficult to determine if the change in GABA reflected normalization of a GABA deficit or an elevation above the normal level. Second, the heterogeneity of our patient population and their concurrent medication treatment raises a potential confound between different causes of GABA elevation. While our inclusion of currently depressed patients with bipolar II disorder may be considered another limitation of this study since it increases sample heterogeneity, this is mitigated by the fact that studying individuals with symptom clusters that may cross diagnostic boundaries is in line with the new US National Institute of Mental Health Research Domain Criteria (RDoC) framework for studying mental disorders. 42, 43 Current SSRI and benzodiazepine use were negatively associated with increase in GABA, suggesting that treatment with these medications may have partially prevented GABA elevations in a subgroup of participants. Third, owing to discomfort, some participants could not be treated at the standard stimulus strength of 120% of MT. Finally, a general limitation related to 1 H MRS is the inability of the standard J-editing method to separate glutamate from glutamine, yielding the composite resonance that is commonly referred to as "Glx." However, we recently obtained preliminary evidence that strongly suggests that the J-edited Glx peak consists primarily of glutamate, with little or no glutamine contribution.
44,45
Conclusion
The major inhibitory neurotransmitter system represented by GABA is at the intersection of the pathophysiology of depression as well as mechanisms of its treatment. Transcranial magnetic stimulation over the left DLPFC improves depressive symptoms, and this is correlated with selective elevations of GABA in the MPFC, which has dense reciprocal connections with the DLPFC. This may indicate both restoration of GABAergic synapses as well as improved homeostatic balance with the potentially excitotoxic glutamatergic system. Future studies should elucidate whether these neurochemical changes mediate plasticity of the resting-state networks that show elevated functional connectivity in patients with depression.
